ANAPTYSBIO, INC

Key metrics

Financial performance

Over the last 9 fiscal years ANAPTYSBIO, INC's revenue grew from $16.68M to $234.60M, a compound annual growth rate of 34.1%. Net profit margin expanded from -25.5% to -5.6% over the same period - every figure below comes from the company's audited annual filings.

Key statistics

Latest filings

Browse the full filing history (681 filings)

Recent press releases

• Anaptys Announces First Quarter 2026 Financial Results and Provides Business Update2026-05-12

  Completed spin-off of First Tracks Biotherapeutics, Inc., its former biopharma operations business

• Anaptys Appoints Chris Murphy as Chief Financial Officer and Owen Hughes to Board of Directors2026-05-11

  Strengthens Leadership Team and Board with additional business development, finance and royalty management expertise

• Anaptys to Participate at the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference2026-05-04

  To register for the conference, please visit https://hcwevents.com/royalty-company-conference .

• Delaware Chancery Court Rules in Favor of Anaptys by Dismissing Tesaro’s Anticipatory Breach Claim2026-04-24

  Ruling preserves current contracted royalty rates and rejects Tesaro’s request for any royalty reduction

• Anaptys Completes Separation of First Tracks Biotherapeutics and Now Exclusively Manages GSK and Vanda Financial Collaborations2026-04-20

  Focused on protecting and returning value of Jemperli and imsidolimab royalties to shareholders

Similar companies

The largest companies sharing ANAPTYSBIO, INC's SEC industry classification (pharmaceutical preparations).